Implications for the therapeutic role of Imatinib in systemic sclerosis: a single-arm meta-analysis

doi:10.5246/jcps.2019.03.019

Abstract

Abstract:

Sclerotic chronic graft-versus-host disease (ScGVHD) or systemic sclerosis (SSc) is one of the most severe manifestations of chronic graft-versus-host disease (cGVHD) since the involvement of major organs significantly affects the mortality and morbidity of SSc patients. Currently, there are no effective therapeutic approaches or standard “second-line” therapy for SSc. Imatinib, a clinical tyrosine kinase inhibitor used to treat chronic myeloid leukemia and gastrointestinal tumor, has shown potential therapeutic effects in treating ScGVHD or SSc. Due to the current limitations of clinical trials using Imatinib in the treatment of SSc, the results vary among different studies, and the applications of Imatinib in SSc is still in vagueness. Here we conducted a single-arm meta-analysis to quantitatively and systematically interpret the results of previous studies, as to evaluate the potential therapeutic effect of Imatinib in SSc. The pooled clinical response rate (CRR) showed that Imatinib had higher CRR in SScpatients with longer disease duration (CRR = 0.550) and lung involvement (CRR = 0.601) than those without (P<0.001). Therefore, it was encouraging to conduct future clinical studies regarding Imatinib therapy in SSc patients, since the global response rate of Imatinib was higher than expected in specific subgroup patients.

Key words: Imatinib, Systemic sclerosis, Sclerotic chronic graft-versus-host disease

CLC Number:

R954

Supporting:

Qi Zhang, Bo Zhang, Nengming Lin. Implications for the therapeutic role of Imatinib in systemic sclerosis: a single-arm meta-analysis[J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(3): 195-202.

References

[1] Jaeger, V.K.; Wirz, E.G.; Allanore, Y.; Riemekasten, G.; Hachulla, E.; Distler, O.; Airò, P.; Carreira, P.E.; Tikly, M.; Vettori, S.; Balbir Gurman, A.; Damjanov, N.; Müller-Ladner, U.; Distler, J.H.W.; Li, M.; Häusermann, P.; Walker, U.A. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis - A 10 year longitudinal study from the eustar database. Ann. Rheum. Dis. 2016, 75, 1285-1292.

[2] Gordon, J.K.; Domsic, R.T. Clinical Trial Design Issues in Systemic Sclerosis: an Update. Curr. Rheumatol. Rep. 2016, 18, 38.

[3] Kowal-Bielecka, B.O.; Landewe, R.; Avouac, J.; Chwiesko, S.; Miniati, I.; Czirjak, L.; Clements, P.;Denton, C.; Farge, D.; Fligelstone, K.; Foldvari, I.; Furst, D.E.; Muller-Ladner, U.; Seibold, J.; Silver, R.M.; Takehara, K.; Toth, B.G.; Tyndall, A.; Valentini, G.; van den Hoogen, F.; Wigley, F.; Zulian, F.; Matucci-Cerinic, M. EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. 2009, 68, 620-628.

[4] Fraser, C.J.; Scott Baker, K. The management and outcome of chronic graft-versus-host disease. Br. J. Haematol. 2007, 138, 131-145.

[5] Guo, L.; Chen, X.X.; Gu, Y.Y.; Zou, H.J.; Ye, S. Low-dose imatinib in the treatment of severe systemic sclerosis: A case series of six Chinese patients and literature review. Clin. Rheumatol. 2012, 31, 1395-1400.

[6] Tian, H.P.; Zhang, J. Efficacy and safety of homoharringtonine during consolidation therapy in chronic myeloid leukemia: A meta-analysis. J. Chin. Pharm. Sci. 2014, 23, 716-722.

[7] Dimitroulas, T.; Daoussis, D.; Garyfallos, A.; Sfikakis, P.P.; Kitas, G.D. Molecular and Cellular Pathways as Treatment Targets for Biologic Therapies in Systemic Sclerosis. Curr. Med. Chem. 2015, 22, 1943-1955.

[8] Korman, B.D.; Criswell, L.A. Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance. Curr. Rheumatol. Rep. 2015, 17, 21.

[9] Assassi, S.; Wu, M.H.; Tan, F.K.; Chang, J.; Graham, T.A.; Furst, D.E.; Khanna, D.; Charles, J.; Ferguson, E.C.; Feghali-Bostwick, C.; Mayes, M.D. Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. Arthritis Rheum. 2013, 65, 2917-2927.

[10] Khanna, D.; Saggar, R.; Mayes, M.D.; Abtin, F.; Clements, P.J.; Maranian, P.; Assassi, S.; Saggar, R.; Singh, R.R.; Furst, D.E. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum. 2011, 63, 3540-3546.

[11] Spiera, R.F.; Gordon, J.K.; Mersten, J.N.; Magro, C.M.; Mehta, M.; Wildman, H.F.; Kloiber, S.; Kirou, K.A.; Lyman, S.; Crow, M.K. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: Results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann. Rheum. Dis. 2011, 70, 1003-1009.

[12] Magro, L.; Mohty, M.; Catteau, B.; Coiteux, V.; Chevallier, P.; Terriou, L.; Jouet, J.P.; Yakoub-Agha, I. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood. 2009, 114, 719-722.

[13] Pope, J.; McBain, D.; Petrlich, L.; Watson, S.; Vanderhoek, L.; de Leon, F.; Seney, S.; Summers, K. Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 2011, 63, 3547-3551.

[14] Arai, S.; Pidala, J.; Pusic, I.; Chai, X.Y.; Jaglowski, S.; Khera, N.; Palmer, J.; Chen, G.L.; Jagasia, M.H.; Mayer, S.A.; Wood, W.A.; Green, M.; Hyun, T.S.; Inamoto, Y.; Storer, B.E.; Miklos, D.B.; Shulman, H.M.; Martin, P.J.; Sarantopoulos, S.; Lee, S.J.; Flowers, M.E.D. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clin. Cancer Res. 2016, 22, 319-327.

[15] Baird, K.; Comis, L.E.; Joe, G.O.; Steinberg, S.M.; Hakim, F.T.; Rose, J.J.; Mitchell, S.A.; Pavletic, S.Z.; Figg, W.D.; Yao, L.; Flanders, K.C.; Takebe, N.; Sarantopoulos, S.; Booher, S.; Cowen, E.W. Imatinib Mesylate for the Treatment of Steroid-Refractory Sclerotic-Type Cutaneous Chronic Graft-versus-Host Disease. Biol. Blood Marrow Transplant. 2015, 21, 1083-1090.

[16] Fraticelli, P.; Gabrielli, B.; Pomponio, G.; Valentini, G.; Bosello, S.; Riboldi, P.; Gerosa, M.; Faggioli, P.; Giacomelli, R.; Del Papa, N.; Gerli, R.; Lunardi, C.; Bombardieri, S.; Malorni, W.; Corvetta, A.; Moroncini, G.; Gabrielli, A. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res. Ther. 2014, 16, R144.

[17] Olivieri, A.; Locatelli, F.; Zecca, M.; Sanna, A.; Cimminiello, M.; Raimondi, R.; Gini, G.; Mordini, N.; Balduzzi, A.; Leoni, P.; Gabrielli, A.; Bacigalupo, A. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood. 2009, 114, 709-718.

[18] Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25, 603-605.

[19] Desbois, A.C.; Cacoub, P. Systemic sclerosis: An update in 2016. Autoimmun. Rev. 2016, 15, 417-426.

[20] Murdaca, G.; Contatore, M.; Gulli, R.; Mandich, P.; Puppo, F. Genetic factors and systemic sclerosis. Autoimmun. Rev. 2016, 15, 427-432.

[21] Yanaba, K. Strategy for treatment of fibrosis in systemic sclerosis: Present and future. J. Dermatol. 2016, 43, 46-55.

[22] Khanna, D.; Denton, C.P.; Jahreis, A.; van Laar, J.M.; Frech, T.M.; Anderson, M.E.; Baron, M.; Chung, L.; Fierlbeck, G.; Lakshminarayanan, S.; Allanore, Y.; Pope, J.E.; Riemekasten, G.; Steen, V.; Müller-Ladner, U.; Lafyatis, R.; Stifano, G.; Spotswood, H.; Chen-Harris, H.; Dziadek, S.; Morimoto, A.; Sornasse, T.; Siegel, J.; Furst, D.E. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016, 387, 2630-2640.

[23] Wells, A.U.; Denton, C.P. Interstitial lung disease in connective tissue disease: Mechanisms and management. Nat. Rev. Rheuml. 2014, 10, 728-739.

[24] Sabnani, I.; Zucker, M.J.; Rosenstein, E.D.; Baran, D.A.; Arroyo, L.H.; Tsang, P.; Zubair, M.; Rivera, V. A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford). 2009, 48, 49-52.

[25] Castillo-Tandazo, W.; González, J.; Flores-Fortty, A. Pathogenesis and therapeutics of interstitial lung disease in systemic sclerosis. Curr. Rheumatol. Rev. 2013, 9, 105-112.

[26] Steen, V.D.; Medsger, T.A., Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum. 2000, 43, 2437-2444.